Main functions, effects and indications of Brigatinib/Brigatinib (Ambre) tablets

Brigatinib/Brigatinib (Brigatinib) is an oral ALK inhibitor, mainly used to treat ALK-positive non-small cell lung cancer (NSCLC). Non-small cell lung cancer is the most common type of lung cancer, and ALK-positive non-small cell lung cancer refers to mutations in the ALK gene in tumor cells. Brigatinib combats the growth of lung cancer by inhibiting the kinase activity of ALK mutations and preventing the proliferation and spread of tumor cells.

The main benefit of brigatinib is its ability to effectively treat patients with ALK-positive non-small cell lung cancer who have developed resistance to otherALK inhibitors such as crizotinib. Specifically, brigatinib is suitable for patients who have failed previous treatments and whose tumors have spread to other parts of the body (i.e., are metastatic). For these patients, brigatinib provides a new treatment option that helps patients control their disease, prolong survival, and improve quality of life by continuously targeting ALK mutations.

Brigatinib is also particularly suitable for patients who are intolerant or have poor response to crizotinib. As an early ALK inhibitor, crizotinib is effective for many patients, but as treatment time increases, some patients may develop drug resistance, leading to disease progression. Brigatinib can overcome the problem of resistance to crizotinib and provide patients with new treatment opportunities. Brigatinib can not only control the growth of tumors, but also effectively delay the progression of the disease and provide sustained disease control.

Overall, brigatinib's mechanism of action and indications make it an important treatment option for patients with ALK-positive non-small cell lung cancer, especially those who have developed resistance to other ALK inhibitors. It provides these patients with an effective treatment and significantly improves their survival rate and quality of life.

Reference materials:https://www.alunbrig.com/